The outlook of companies tied to Sildenafil's history presents a intricate investment landscape. While the initial success generated substantial returns , generic copies have significantly eroded market share . Investing in related pharmaceutical companies now requires a discerning assessment of patent safeguards, evolving medical shifts , and the